Tanibirumab (TTAC-0001): A Fully Human Monoclonal Antibody Targets Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2)

被引：29
|
作者：
Lee, Sang Hoon [1 ]
机构：
[1] PharmAbcine, Taejon 305811, South Korea
来源：
ARCHIVES OF PHARMACAL RESEARCH | 2011年 / 34卷 / 08期
关键词：
TUMOR ANGIOGENESIS; THERAPY; DISEASE;
D O I：
10.1007/s12272-011-0821-9
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor growth and metastasis. Several anticancer therapies targeting VEGFR with small molecules and antibody have been currently studied in preclinical and clinical studies. This article provides a review of human monoclonal antibody tanibirumab (TTAC-0001), which specifically binds VEGFR-2 and is currently being developed in preclinical stage by PharmAbcine (Daejon, Korea).
引用
收藏
页码：1223 / 1226
页数：4
相关论文
共 50 条
  • [1] Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
    Sang Hoon Lee
    Archives of Pharmacal Research, 2011, 34 : 1223 - 1226
  • [2] Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis
    Kim, Dong Geon
    Jin, Younggeon
    Jin, Juyoun
    Yang, Heekyoung
    Joo, Kyeung Min
    Lee, Weon Sup
    Shim, Sang Ryeol
    Kim, Sung-Woo
    Yoo, Jinsang
    Lee, Sang Hoon
    Yoo, Jin-San
    Nam, Do-Hyun
    MABS, 2015, 7 (06) : 1195 - 1204
  • [3] TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
    Lee, Weon Sup
    Pyun, Bo-Jeong
    Kim, Sung-Woo
    Shim, Sang Ryeol
    Nam, Ju Ryoung
    Yoo, Ji Young
    Jin, Younggeon
    Jin, Juyoun
    Kwon, Young-Guen
    Yun, Chae-Ok
    Nam, Do-Hyun
    Oh, Keunhee
    Lee, Dong-Sup
    Lee, Sang Hoon
    Yoo, Jin-San
    MABS, 2015, 7 (05) : 957 - 968
  • [4] TTAC-0001, anti-VEGFR2/KDR monoclonal antibody, inhibits VEGFR signaling and tumor growth in preclinical models
    Jin, Younggeon
    Jin, Juyoun
    Yang, Heekyoung
    Park, Minjae
    Lee, Weon Sup
    Kim, Sung-Woo
    Shim, Sang Ryeol
    Kim, Yeonjoo
    Lee, Sang Hoon
    Yoo, Jin-San
    Seol, Ho Jun
    Nam, Do-Hyun
    CANCER RESEARCH, 2011, 71
  • [5] TTAC-0001, fully human anti-VEGFR2/KDR neutralizing antibody blocks tumor angiogenesis and tumor growth
    Lee, Weon Sup
    Pyun, Bo-Jeong
    Kim, Sung-Woo
    Shim, Sang Ryeol
    Yoo, Hyeon-Mi
    Oh, Keunhee
    Lee, Dong-Sup
    Yoo, Ji-Young
    Yun, Chae-Ok
    Kwon, Young-Guen
    Lee, Sang Hoon
    Yoo, Jin-San
    CANCER RESEARCH, 2011, 71
  • [6] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
    Su Jin Lee
    Seon Young Lee
    Weon Sup Lee
    Jin San Yoo
    Jong-Mu Sun
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Myung-Ju Ahn
    Ho Yeong Lim
    Won Ki Kang
    Young Suk Park
    Investigational New Drugs, 2017, 35 : 782 - 790
  • [7] Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
    Lee, Su Jin
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin San
    Sun, Jong-Mu
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Ahn, Myung-Ju
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 782 - 790
  • [8] VASCULAR ENDOTHELIAL GROWTH FACTOR A AND ITS RECEPTOR VEGFR-2 IN THE FELINE PLACENTA
    Gomez Castro, Gimena
    Barbeito, Claudio
    Merkis, Cecilia
    Casas, Luciano
    Diessler, Monica
    PLACENTA, 2022, 122 : E102 - E102
  • [9] Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
    Lee, Su Jin
    Ham, Jun Soo
    Kim, Hee Kyung
    Byeon, Seonggyu
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin San
    Sun, Jong Mu
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Ahn, Myung-Ju
    Lim, Ho Yeong
    Kang, Won Ki
    Park, Young Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Intravitreal Tanibirumab, a Fully Human Monoclonal Antibody against Vascular Endothelial Growth Factor Receptor 2, Suppresses and Regresses Laser-induced Choroidal Neovascularization in a Rat Model
    Kim, Jaeryung
    Shim, Sang Ryeol
    Kim, Sung-Woo
    Lee, Weon Sup
    Yoo, Jin-San
    Lee, Sang Hoon
    Kim, Sang Jin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
12345